C.H. Boehringer Sohn AG & Co. KG
Research-driven biopharmaceutical company active in human and animal health
of 100 · stable trend · Strong moral/spiritual alignment
Standing
62/100
Raw Score
54/85
Confidence
82%
Evidence
Strong
About
A large family-owned pharmaceutical group with strong long-term research and access contributions, but repeated integrity failures keep alignment mixed.
Boehringer Ingelheim shows durable social value through medicine development, animal health work, access efforts, and continued research investment. Its public record also includes major compliance failures, litigation settlements, and cartel-related enforcement, which materially weakens integrity. The overall pattern is a capable institution with meaningful public benefit, but inconsistent moral alignment under commercial pressure.
Five Pillars
Pillar scores (0–100%)
Boehringer Ingelheim shows durable social value through medicine development, animal health work, access efforts, and continued research investment. Its public record also includes major compliance failures, litigation settlements, and cartel-related enforcement, which materially weakens integrity. The overall pattern is a capable institution with meaningful public benefit, but inconsistent moral alignment under commercial pressure.
17 Criteria Scores
Individual item scores (0–5) with evidence notes
Core Worldview
Contribution to Others
Personal Discipline
Reliability
Stability Under Pressure
Timeline
Key events and documented turning points
Albert Boehringer founds the company in Ingelheim
The company traces its origin to Albert Boehringer’s founding of the business in Ingelheim am Rhein, establishing the base for the later global group.
→ Created the institutional base for a long-running family-owned pharmaceutical group.
4U.S. Justice Department announces $95 million off-label and kickback settlement
Federal authorities said Boehringer Ingelheim Pharmaceuticals, Inc. would pay $95 million to resolve allegations involving off-label promotion and kickbacks tied to several drugs.
→ Large financial settlement and a documented compliance failure in commercial conduct.
4Company announces $650 million U.S. Pradaxa litigation settlement
Boehringer Ingelheim announced a comprehensive settlement covering about 4,000 U.S. claims tied to serious bleeding events associated with Pradaxa.
→ Major mass-tort settlement addressing widespread safety-related claims without a trial verdict on every case.
4Brazilian antitrust authority signs agreement in pharmaceutical cartel investigation
CADE announced a settlement agreement connected to an international pharmaceutical cartel investigation involving Boehringer Ingelheim entities and individuals.
→ Another serious integrity hit tied to competition conduct, with financial and legal consequences.
4Ranks in the top ten of the 2024 Access to Medicine Index
The Access to Medicine Foundation ranked Boehringer Ingelheim eighth, highlighting product delivery and access work while also noting limits in low-income country coverage.
→ Independent recognition for access-oriented delivery, though not without remaining gaps.
3Reports strong 2024 results, heavy R&D spending, and access-related delivery
Boehringer Ingelheim reported 2024 net sales of EUR 27.751 billion, R&D investment of about EUR 6.4 billion, 48 million rabies vaccine doses delivered, and more than 162,000 patients reached through donation programs.
→ Shows sustained capacity to invest in innovation and deliver some measurable public-health benefits at scale.
5Second Circuit rejects challenge to Medicare drug-price negotiation program
A federal appeals court rejected Boehringer Ingelheim’s challenge to the Medicare Drug Price Negotiation Program, underscoring the company’s willingness to press pricing and market-position arguments under policy pressure.
→ The institution did not prevail in court; the episode highlights how it behaves when public policy constrains revenue expectations.
3Pressure Tests
Behavior under crisis or scrutiny
Regulatory and compliance scrutiny
2023Large settlements and cartel-related enforcement tested the company’s public commitments.
Response: It settled or entered agreements while continuing operations and public responsibility messaging.
mixedPublic-health pricing pressure
2025The company litigated against Medicare drug-price negotiation rules.
Response: It pursued a legal challenge and lost on appeal.
mixedProgression
crisis years
Compliance, litigation, and competition failures constrained trust.
downcurrent stage
Recent access delivery strengthens social value but not enough to erase integrity deficits.
flatearly years
Family-owned long-horizon governance established a durable institutional base.
upgrowth years
Global R&D and product reach expanded social impact.
upBehavioral Patterns
Positive
- • Long-horizon family ownership supports sustained research investment and reduces pure quarter-to-quarter pressure.
- • Independent access benchmarking and public-health delivery data show real, repeated social contribution.
- • The company has meaningful global reach in both human and animal health.
Concerns
- • Serious integrity failures recur in different forms, including promotion, pricing, and competition conduct.
- • Public-benefit claims are consistently limited by commercial and legal conflict around major products.
- • Pressure handling often favors defensive legal and market-position tactics rather than visible public-interest restraint.
Evidence Quality
7
Strong
2
Medium
1
Weak
Overall: strong
Assessment reflects observable institutional conduct and public evidence, not hidden intention.